What Altis Biosystems does

Altis Biosystems is a privately held biotechnology company founded in 2015 and headquartered in Durham, North Carolina, that develops human intestinal epithelium models derived from adult donor stem cells for preclinical drug discovery and toxicology applications. Its core platform, RepliGut Systems, comprises RepliGut Planar (a reproducible, scalable human intestinal monolayer for drug disposition, pharmacology, ADME/DMPK, toxicity, and efficacy studies), RepliGut Crypt (capturing intestinal crypt architecture), and RepliGut Immune Co-Culture (a gut-immune model for inflammatory bowel disease research), complemented by catalog kit products and a human intestinal mucus offering.

The company monetizes through a hybrid B2B model: direct sales of ready-to-use kits and media products to pharma and biotech researchers, and fee-for-service contract research engagements including InflammaScreen (inflammation screening), StemTox (toxicity assessment), In Vitro DMPK, and custom research services. Pricing is not publicly disclosed; customers engage via website contact forms and direct sales outreach with multi-year contract terms typical of the life sciences tools segment. RepliGut products are positioned as New Approach Methodologies (NAMs) providing human-relevant, ethically sourced alternatives to animal testing for gastrointestinal toxicity prediction, drug absorption, metabolism, barrier function, and inflammatory response.

Altis serves pharmaceutical companies, biotechnology companies, and academic and contract research organizations, with named collaborations including Janssen R&D, Genentech, Fog Pharma, and CN Bio Innovations. The company maintains a scientific-publication-led go-to-market motion, leveraging peer-reviewed journals, conference presentations, and direct enterprise engagement, with Japan distribution handled via a partnership with Funakoshi, Ltd. As of April 2025, the company had raised approximately $6.6 million in disclosed equity funding across multiple rounds from investors including Hatteras Venture Partners, VentureSouth, and New Orleans BioFund, and operates with 11-50 employees organized around R&D, commercial strategy, operations, and quality assurance functions.

Name

Altis Biosystems

Legal name

Altis Biosystems, Inc.

Website

https://altisbiosystems.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Altis Biosystems is a Durham, NC-based biotechnology company developing RepliGut Systems, stem-cell-derived human intestinal epithelium models used by pharmaceutical and biotechnology companies for preclinical drug discovery, toxicology screening, and ADME/DMPK studies as alternatives to animal testing.

Ownership category

akta.pro rank

Product category

Preclinical Drug Discovery Tools

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

Keywords

• Organ-on-chip models
• Preclinical drug discovery
• Human intestinal models
• Stem cell assays
• GI toxicity screening

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. RepliGut Kit Sales: Sale of ready-to-use RepliGut Planar kits, RepliGut Crypt kits, and associated media products for compound screening, disease modeling, and microbiome research.
2. Contract Research Services: Fee-for-service offerings including InflammaScreen (inflammation screening), StemTox (toxicity assessment), and In Vitro DMPK studies conducted on behalf of pharmaceutical and biotech clients.
3. Custom Service Engagements: Bespoke research collaborations tailored to specific client drug development needs, leveraging the company's human intestinal model platform.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Altis Biosystems develops and sells RepliGut Systems, a collection of in vitro human intestinal models derived from adult donor stem cells that replicate the structure of human small intestine and colonic epithelium. The portfolio includes RepliGut Planar, RepliGut Crypt, and RepliGut Immune Co-Culture platforms, complemented by ready-to-use RepliGut Kits, Intestinal Mucus products, and contract research services (InflammaScreen, StemTox, In Vitro DMPK, and Custom Services) for preclinical drug discovery, toxicology, ADME, and disease modeling applications.

Product overview

Altis Biosystems offers RepliGut® Systems, a collection of in vitro human intestinal models derived from stem cells, designed for pre-clinical drug discovery. The portfolio consists of three platform products (RepliGut® Planar, RepliGut® Crypt, and RepliGut® Immune Co-Culture) that replicate the complex structure of human small intestine and colonic epithelium. These are complemented by kit products (RepliGut® Kits and Intestinal Mucus) for laboratory use, and service offerings (InflammaScreen, StemTox, In Vitro DMPK, and Custom Services) that enable pharmaceutical companies to screen compounds for GI toxicity, evaluate inflammatory responses, and assess drug metabolism and bioavailability—all as alternatives to animal testing through New Approach Methodologies (NAMs).

Differentiator

Problem solved

Functional benefit

Products and services

• RepliGut® Planar A reproducible and scalable human intestine platform derived from adult donor stem cells, suitable for studying drug disposition, pharmacology, toxicity, metabolism, drug absorption, and efficacy in preclinical drug discovery. Designed for high-throughput compound screening in standard laboratory formats.
• RepliGut® Crypt An in vitro model derived from stem cells designed to replicate the complex cellular lifecycle of the intestinal crypt for drug discovery applications, capturing the crypt architecture of the human intestine for more physiologically relevant drug testing.
• RepliGut® Immune Co-Culture A human gut-immune co-culture model for evaluating inflammatory bowel disease anti-inflammatory therapies, enabling researchers to assess immune and epithelial interactions in a physiologically relevant format.
• RepliGut® Kits Ready-to-use kit products containing RepliGut® Planar models and media for compound screening, disease modeling, drug disposition analysis, and toxicity assessments in customer laboratories.
• Intestinal Mucus Human mucus harvested from the RepliGut® Planar platform for research related to gastrointestinal tract disorders, microbiome studies, and drug delivery investigations.
• InflammaScreen Inflammation screening service using RepliGut® models to evaluate pro- and anti-inflammatory effects of new therapeutic modalities on human intestinal models.
• StemTox Stem cell-based toxicity screening service for predicting gastrointestinal toxicity risk of therapeutic agents using RepliGut® models.
• In Vitro DMPK Drug metabolism and pharmacokinetics service using human intestinal models to assess oral bioavailability, drug disposition, and ADME properties.
• Custom Services Bespoke research collaborations tailored to specific client drug development needs, leveraging the RepliGut® Systems platform for custom preclinical studies.

Quantifiable outcome

• High-throughput assay for predicting diarrhea risk achieved 91% accuracy for proliferation, 90% for abundance, and 88% for barrier formation using RepliGut Planar model
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Three partnerships are on record, tiered core, regional and minor.

• CN Bio InnovationscoreStrategic or Co-development PartnerAltis and CN Bio partnered to combine their RepliGut Planar-Jejunum and PhysioMimix Liver-on-a-Chip models, creating a primary human microphysiological system (MPS) that simulates oral drug administration. This Gut/Liver model enhances translation of in vitro studies to in vivo results and improves accuracy and predictability of data. It represents the next generation of CN Bio's oral bioavailability assay.
• Funakoshi, Ltd.regionalChannel Partner/ Reseller/ DistributorFunakoshi, a Japanese leader in supplying research reagents and instruments for life science researchers, serves as an authorized distributor of all RepliGut Planar kits and RepliGut Media in Japan, enabling broader access to Altis products in the Japanese market.
• GenentechminorStrategic or Co-development PartnerResearch collaboration in which RepliGut Planar Jejunum was evaluated for gene expression patterns in response to prototypical metabolic inducers (Rifampin, CITCO, 3-MC, and Calcitriol) at the 25th North American ISSX conference. Published scientific collaboration demonstrating platform utility.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• TissUse: Direct peer offering multi-organ MPS ("human-on-a-chip") for toxicology and ADME applications. Competes in the same multi-organ MPS category that Altis enters via its CN Bio partnership.
• Mimetas: Direct peer providing the OrganoPlate platform for organ-on-chip and 3D tissue models used in preclinical drug discovery. Comparable customer base in pharma/biotech and similar NAMs positioning to Altis Biosystems.
• CN Bio Innovations: Direct peer and active partner, developing PhysioMimix single- and multi-organ MPS including Liver-on-a-Chip. Competitor in gut/liver ADME and oral bioavailability services, and co-developer with Altis on the Gut/Liver MPS.
• InSphero: Direct peer in 3D microtissue and organotypic models for drug discovery and toxicology, including liver and pancreatic islet models. Overlaps with Altis on preclinical drug-discovery services and NAMs positioning.
• Emulate: Direct peer offering organ-on-chip platforms (Liver-Chip, Intestine-Chip, Lung-Chip) used for preclinical drug discovery. Comparable product category, customer base (large pharma), and NAMs regulatory positioning to Altis Biosystems.

Broad incumbents

• Organovo: Broad incumbent in 3D bioprinted tissue and disease modeling for preclinical research. Provides overlapping but more general 3D-tissue capabilities versus Altis's specialized intestinal organoid platform.
• Molecular Devices: Broad incumbent life sciences instrument and cell-line screening vendor serving pharma/biotech R&D. Adjacent to Altis on the screening-tools and assay-readout side of NAMs workflows.

Emerging players

• Cypre Holdings (SynVivo/Cypher): Emerging player in vascularized organ-on-chip and 3D tissue models for drug discovery. Comparable NAMs positioning and overlapping pharma customer base to Altis Biosystems.
• DefiniGEN: Emerging player in iPSC-derived human cell models (hepatocytes, intestinal, pancreatic) for drug discovery. Comparable technology base (iPSC-derived models) and customer base to Altis Biosystems.
• Cellbox Labs: Emerging player developing automated MPS platforms that leverage RepliGut cells. Direct technology integration partner and partial competitor in automated intestinal MPS offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/altisbiosystems
• Xx.com/AltisBioInc

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds8 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altis Biosystems